Crescent Biopharma Secures $185M Funding as ASCEND Trial Advances
Event summary
- $185M private placement completed in December 2025, extending cash runway into 2028.
- ASCEND Phase 1/2 trial for CR-001 (PD-1 x VEGF bispecific antibody) initiated in February 2026.
- Strategic partnership with Kelun-Biotech expands pipeline and combination strategies.
- Three additional clinical trials expected to launch in 2026 across the portfolio.
The big picture
Crescent Biopharma's funding and pipeline expansion reflect a broader trend in oncology toward bispecific antibodies and ADCs as next-generation therapies. The $185M private placement underscores investor confidence in its combination strategy, though execution risks remain high given the competitive landscape of immuno-oncology.
What we're watching
- Clinical Execution
- The pace at which Crescent delivers proof-of-concept data for CR-001 and other candidates will determine its near-term valuation.
- Combination Strategy
- Whether the partnership with Kelun-Biotech accelerates regulatory approvals and commercialization timelines for key assets.
- Cash Management
- How Crescent allocates its $213M cash position to balance aggressive clinical development while maintaining runway into 2028.
Related topics